A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment
Top Cited Papers
- 20 February 2020
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (8) , 692-694
- https://doi.org/10.1056/nejmp2000929
Abstract
A novel coronavirus, designated as 2019-nCoV, emerged in Wuhan, China, at the end of 2019. As of January 24, 2020, at least 830 cases had been diagnosed in nine countries: China, Thailand, Japan, South Korea, Singapore, Vietnam, Taiwan, Nepal, and the United States. Twenty-six fatalities occurred, mainly in patients who had serious underlying illness.1 Although many details of the emergence of this virus — such as its origin and its ability to spread among humans — remain unknown, an increasing number of cases appear to have resulted from human-to-human transmission. Given the severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak in 2002 and the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in 2012,2 2019-nCoV is the third coronavirus to emerge in the human population in the past two decades — an emergence that has put global public health institutions on high alert.This publication has 3 references indexed in Scilit:
- SARS and MERS: recent insights into emerging coronavirusesNature Reviews Microbiology, 2016
- Transmission characteristics of MERS and SARS in the healthcare setting: a comparative studyBMC Medicine, 2015
- Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methodsBMC Public Health, 2014